Press / Special articles

Press / Special articles » Press releases

Detailed view

Date: 15.06.2015 11:14

Efficient biofilm management: without pain or side-effects The HELBO®-Therapy: looking back at the IDS 2015

The HELBO®-Therapy, is a clinically proven photodynamic procedure, which combats bacterial infections in the oral cavity. Many users have been employing this therapy for a number of years and value it highly. At this year's International Dental Show (IDS) in Cologne, there was once again a great number of open-minded, interested parties, who wanted to find out more about the antimicrobial photodynamic therapy from a market leader.

However, the slogan „pain-free“ couldn’t be applied to the HELBO® team at the IDS. The team was standing from morning until evening, and aching feet could hardly be avoided. Nethertheless, every single member of the team was full of energy right until the end. This was due to the great number of visitors, which could be seen at the HELBO® corner of the bredent group exhibition stand. Many interested parties sought detailed information about the HELBO® -Therapy. The team was able to answer all open queries about the range of indications, the clinical procedure, the prices, as well as highlight how this therapy differs from the competition.

The HELBO®-Therapy reduces infection-causing pathogenic bacteria by over 99 % and completely without side-effects. In this procedure, which has been scientifically researched and documented in a variety of indications for more than twelve years, the microorganisms are first stained (HELBO® Blue Photosensitizer) and finally exposed under the HELBO® TheraLite Laser®, a non-thermally acting laser. The laser light forms highly reactive singlet oxygen which leads to lipid oxidation of the bacteria's membrane, thus destroying pathogenic bacteria in the shortest possible time-frame. The procedure is both pain and side-effect free, and in many cases eliminates the need for invasive measures which patients are less willing to accept. Over 70 publications document evidence in support of this therapy. Now, in addition to this, the DVK has issued a recommendation for the reimbursement of treatments for biofilm-associated infections of the oral cavity (periodontology, periimplantitis therapy), if certain conditions are fulfilled. The HELBO®-Therapy procedure has fulfilled these criteria for a long time and has gained full approval in conjunction with the evidence supporting the effectiveness of this therapy.

Photosensitizer) and finally exposed under the HELBO® TheraLite Laser®, a non-thermally acting laser. The laser light forms highly reactive singlet oxygen which leads to lipid oxidation of the bacteria's membrane, thus destroying pathogenic bacteria in the shortest possible time-frame. The procedure is both pain and side-effect free, and in many cases eliminates the need for invasive measures which patients are less willing to accept. Over 70 publications document evidence in support of this therapy. Now, in addition to this, the DVK has issued a recommendation for the reimbursement of treatments for biofilm-associated infections of the oral cavity (periodontology, periimplantitis therapy), if certain conditions are fulfilled. The HELBO®-Therapy procedure has fulfilled these criteria for a long time and has gained full approval in conjunction with the evidence supporting the effectiveness of this therapy.


Information on HELBO® therapy is available at: www.helbo.de.


The bredent group is an internationally-active, family-run company.

It develops and produces optimally coordinated stand-alone products, system solutions (e.g. in implant prosthetics) and "Made in Germany" treatment concepts. These enable dentists and dental technicians to produce and maintain high-quality, cost-effective aesthetic restorations that ensure periodontal hygiene.

The bredent group strives to be amongst the best. That is why the employees are always ready to deliver excellence for our clients and their patients, with the necessary flexibility and openness.

With its expertise and innovative drive, the bredent group is the paradigm for the dental market.



Press contact:

Ulrike Vizethum
bredent medical GmbH & Co.KG
Geschäftsbereich HELBO
Josef-Reiert-Straße 4
D-69190 Walldorf
T (+49) 06227/53960-0
F (+49) 06227/53960-11
ulrike.vizethum@helbo.de